A key drawback of the traditional 3+3 design in dose escalation is its slow processing of data to reach the target dose. In contrast, the Continual Reassessment Method designs produce an expedited convergence to the target dose or the doses near target.

Statisticians are familiar with the long standing debate regarding Frequentists Vs Bayesian methodologies and the benefits (or negatives) that each present to a particular situation. However, we are now experiencing a rise in traditional frequentists using Bayesian statistics. What are the reasons behind this? While complex, we can identify two high level points.

Following on from our previous blog post, The Most Popular Clinical Trial Drugs of 2016, we thought it would be a good idea to take a closer look at the Top 10 Corporate Clinical Trial Sponsors of 2016.

In this post, we explore these Top 10 companies, looking at their developmental histories as well as the drugs they have developed and the number of subjects required for their 2016 registered trials.

In part 3/3 of this mini series, Head of Statistics at Statsols - Ronan Fitzpatrick - examines key trends in sample size determination which are being felt in trial design.

In part 2/3 of this mini series, Head of Statistics at Statsols - Ronan Fitzpatrick - examines key trends in sample size determination which are being felt in trial design.

In part 1/3 of this mini series, Head of Statistics at Statsols - Ronan Fitzpatrick - examines key trends in sample size determination which are being felt in trial design.

Currently there are over 205,000 registered clinical trials underway throughout the globe. In 2016 over 14,000 new trials were initiated and we thought it would be useful to look at the top drugs under investigation for the year just past.

How do you reduce sample size in clinical trials? Reducing sample size without losing power can be accomplished in one of three principles. This paper examines these methods and demonstrates 15 ways to reduce sample size in clinical trials.